剪接因子SF2/ASF在胰腺癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2023.03.009

Abstract

Abstract: OBJECTIVE：To investigate expression of the splicing factor 2/alternative splicing factor (SF2/ASF) in pancreatic cancer tissues and its correlation with oncogene P53 (mutant type)，proliferation marker Ki67 and clinicopathological features. METHODS：Differences in expression of the SRSF1 gene (the gene encoding SF2/ASF) in 350 pancreatic cancer tissues and normal tissues adjacent to the cancer were evaluated based on GEPIA database analysis；and correlations with SRSF1 and TP53 and MKi67 were analyzed. In addition， expression of SF2/ASF，mutant P53 and Ki67 protein in 60 pancreatic cancer tissues and corresponding normal tissues were evaluated，as well as correlations between SF2/ASF and mutant P53 and Ki67 using Pearson correlation analysis，and correlations between SF2/AFS protein expression levels and clinicopathological indices of pancreatic cancer patients，and prognostic analysis using Cox proportional risk regression model. RESULTS：Results from our database analysis show that expression of the SRSF1 gene was significantly higher in pancreatic cancer tissues compared with normal tissues (P<0.01)，and expression of the SRSF1 was correlated with both TP53 and MKi67 (r=0.28 and 0.32，respectively，both P<0.01). Results from the immunohistochemical assay and the Pearson correlation analysis show that SF2/ASF was correlated with mutant P53 protein and Ki67 proliferation index (r=-0.386 and 0.275，respectively，P<0.05) in pancreatic cancer tissues. The chi-square test show that expression of the SF2/ASF in pancreatic cancer was correlated with the degree of pancreatic cancer differentiation (P<0.01)，whether with lymph node metastasis (P<0.01) and the presence of distal organ metastasis (P<0.01)，but not with the site of pancreatic cancer occurrence and TNM stage (P>0.05). Cox risk regression analysis show that high expression of SF2/ASF and patient age (both P<0.01) were independent risk factors for overall patient survival. CONCLUSION：SF2/ASF，mutant P53 and Ki67 proteins were highly expressed in pancreatic cancer，and SF2/ASF correlates with mutant P53 and Ki67. Our findings suggest that SF2/ASF can serve as a new target for pancreatic cancer diagnosis and treatment.

Key words: cancerous pancreatic, splicing factor 2/alternative splicing factor, mutant P53, Ki67, immunohistochemistry

CLC Number:

R735.9

MENG Lin, YANG Huayu, MA Xiumei. Expression of the splicing factor SF2/ASF in pancreatic cancer tissues and its relationship with clinicopathological features[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 209-214.

References

[1] GORAL V. Pancreatic cancer:pathogenesis and diagnosis[J]. Asian Pac J Cancer Prev, 2015, 16(14):5619-5624.
[2] NOË M, HONG S M, WOOD L D, et al. Pancreatic cancer pathology viewed in the light of evolution[J]. Cancer Metastasis Rev, 2021, 40(3):661-674.
[3] ZHAO Y W, ZHU T, ZHANG X Y, et al. Splicing factor 2/alternative splicing factor contributes to extracellular signal-regulated kinase activation in hepatocellular carcinoma cells[J]. Mol Med Rep, 2015, 12(3):3890-3894.
[4] IBBA G, PIU C, ULERI E, et al. Disruption by SaCas9 endonuclease of HERV-Kenv, a retroviral gene with oncogenic and neuropathogenic potential, inhibits molecules involved in cancer and amyotrophic lateral sclerosis[J]. Viruses, 2018, 10(8):412.
[5] LIU J, ZHANG C, HU W W, et al. Tumor suppressor p53 and metabolism[J]. J Mol Cell Biol, 2019, 11(4):284-292.
[6] LI J, WANG A R, CHEN X D, et al. Ki67 for evaluating the prognosis of gastrointestinal stromal tumors:a systematic review and meta-analysis[J]. Oncol Lett, 2022, 23(6):189.
[7] YANG C, ZHANG J, DING M, et al. Ki67 targeted strategies for cancer therapy[J]. Clin Transl Oncol, 2018, 20(5):570-575.
[8] RAWLA P, SUNKARA T, GADUPUTI V. Epidemiology of pancreatic cancer:global trends, etiology and risk factors[J]. World J Oncol, 2019, 10(1):10-27.
[9] 王旭, 程合, 刘辰, 等. 2022年度胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(1):1-13.
[10] 任刚, 郑吉春, 张恒恒, 等. 胰腺癌组织中Ki67、p53的表达及其与高剂量少分次放疗生存时间的关系[J]. 现代肿瘤医学, 2022, 30(17):3156-3159.
[11] PIU C, IBBA G, BERTOLI D, et al. Early reduction of the splicing factor 2/alternative splicing factor:a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy[J]. J Neurovirol, 2020, 26(1):133-137.
[12] 郜慧芳, 张寒, 裴珮, 等. 剪接因子SF₂/ASF在儿童白血病细胞中的表达[J]. 首都医科大学学报, 2009, 30(3):273-276.
[13] GUO R, LI Y, NING J Y, et al. HnRNP A1/A2 and SF₂/ASF regulate alternative splicing of interferon regulatory factor-3 and affect immunomodulatory functions in human non-small cell lung cancer cells[J]. PLoS One, 2013, 8(4):e62729.
[14] EZPONDA T, PAJARES M J, AGORRETA J, et al. The oncoprotein SF₂/ASF promotes non-small cell lung cancer survival by enhancing survivin expression[J]. Clin Cancer Res, 2010, 16(16):4113-4125.
[15] FAUSTINO N A, COOPER T A. Pre-mRNA splicing and hunman disease[J].Genes Dev, 2003, 17(4):419-437.
[16] KANAPATHIPILLAI M. Treating p53 mutant aggregation-associated cancer[J]. Cancers, 2018, 10(6):154.
[17] GHIGNA C, GIORDANO S, SHEN H H, et al. Cell motility is controlled by SF₂/ASF through alternative splicing of the Ron protooncogene[J]. Mol Cell, 2005, 20(6):881-890.
[18] XU X D, YANG D M, DING J H, et al. ASF/SF₂-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle[J]. Cell, 2005, 120(1):59-72.
[19] LI L T, JIANG G, CHEN Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer (review)[J]. Mol Med Rep, 2015, 11(3):1566-1572.

Expression of the splicing factor SF2/ASF in pancreatic cancer tissues and its relationship with clinicopathological features

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	WANG Rui, LIU Ying, WU Juan, JI Xiaokun, MA Yang, GUO Xiao, DU Yun. CXCR4, Ki67, MDM2 and N-cadherin expressions in lung adenocarcinoma pleural effusion cells and their correlation with EGFR mutation status [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 114-118.
[2]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[3]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[4]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[5]	YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.
[6]	HUANG Zhuangcheng, WANG Honghao, SHEN Peilin, LIN Ming'en, HE Xuejun. Expression and clinical significance of Notch signalingrelated proteins in cystitis glandularis and bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 374-377,383.
[7]	YANG Xingxiao, ZOU Naiyi, LI Qiaofang, ZHANG Xueyuan, SONG Heng, LIU Zhikun, MA Ming, SHAN Baoen, ZHU Shuchai. Significance in expression of RNF2 and PCNA proteins in esophageal squamous cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 254-257.
[8]	LI Yang, XING Long, MOHAMMED H, MA Xiaolong, XIE Fuqiang, FENG Zhenghu, CHE Yinfu. Clinicopathological significance of expression of thioredoxin and its reductase-1 in tongue squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(2): 87-91.
[9]	MA Kun, WU Haoyu, LI Peng, WANG Li, LI Baixiang. Induction of dopaminergic neuron degeneration by atrazine in substantia nigra in adolescent rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 251-255.
[10]	LIU Dezhong, CHANG Bo, LIN Feixiang, LI Xuedong. β-catenin expression in hepatocellular carcinoma and its effect on prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 300-303.
[11]	FENG Shuitu, CHEN Yide, CHEN Yuqiang, LIN Yubiao, ZHENG Wenhui. Differential expression of Gadd45α in Helicobacter Pylori-infected human gastric cancer and clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(5): 353-358,392.
[12]	ZHAI Xiaoran, JIANG Mei, ZHAO Xiaoting, GU Meng, YUE Wentao. Clinical significance of PFTK1 expression in human non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(3): 231-235.
[13]	CHEN Guangcan, HONG Liangli, HUANG Jiexiong, XIE Aosi, GUO Dan, LIU Shuhui. Expression of GST-π and P-gp in gastric cardia cancer and their clinical significance in the Chaoshan high risk area [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 36-40.
[14]	QIN Jiesheng, HONG Liangli, LIN Xuni, WANG Huige, QIU Qiancheng. Expression and significance of Sema4C in laryngeal squamous carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(3): 230-233.
[15]	FANG Shaobin, DENG Xiaoling, CHEN Jun, CHEN Yonghui, XU Mingyan. The expression and clinical relevance of integrin αvβ6 and JunB in oral squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(3): 234-238,241.